What versions of platinib are available?

Introduction: Platinib is an oral RET receptor tyrosine kinase inhibitor. It is the first selective RET inhibitor approved for marketing in China. It can inhibit the phosphorylation of RET and its downstream molecules, and effectively inhibit the proliferation of cells expressing RET gene mutations.

Platinib is used to treat certain types of non-small cell lung cancer (NSCLC) in adults that have spread to other parts of the body, and to treat certain types of thyroid cancer that are getting worse or have spread to other parts of the body in adults and children 12 years and older.

What are the versions of Platinib?

has many versions, including original version and generic version. The original drug Platinib is developed and produced by Blueprint Medicines-pralsetinib-Gavreto in the United States. In addition, CStone Pharmaceuticals of China also produces Platinib. The trade name is Pujihua. It is also a version of the original drug and has been included in medical insurance. In China, platinib was applied for by CStone Pharmaceuticals and received conditional approval from the State Food and Drug Administration for marketing in March 2021.

There are many generic versions of Platinib, the more common ones are Lucius Pharmaceuticals of Laos, Daxiong Pharmaceuticals of Laos, Indal Pharmaceuticals of India, Lucius Pharmaceuticals of India, etc. The specifications and prices of generics of Platinib produced by different manufacturers are also different.

How to take Platinib

Platinib is an oral capsule. It is usually taken once a day on an empty stomach, at least 2 hours before a meal or at least 1 hour after a meal. Take Platinib at about the same time every day. Take platinib exactly as directed by your doctor, do not take too much or too little, or more often than prescribed. If vomiting occurs after taking this dose, do not take another dose and continue taking your medication as usual. If certain side effects occur, your doctor may reduce your dose or stop treatment with platinib temporarily or permanently.

The therapeutic effect of Platinib

A study of 237 patients with locally advanced or metastatic RET fusion-positive NSCLC confirmed , and the patients received Platinib until disease progression or unacceptable toxicity. Among 107 treatment-naïve patients, the ORR was 78% and the median DOR was 13.4 months. Among 130 patients who had previously received platinum-based chemotherapy, the ORR was 63% and the median DOR was 38.8 months. The most common adverse reactions were musculoskeletal pain, constipation, hypertension, diarrhea, fatigue, edema, pyrexia, and cough.